Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mepha LLC

Division of Teva Pharmaceutical Industries Ltd.
www.mepha.com

Latest From Mepha LLC

Deals In Depth: December 2011

Janssen paid $150 million for Pharmacyclics’ Phase II Btk inhibitor, 2011’s largest up-front for a single asset. Alexion acquired rare disease developer Enobia for just over $1 billion in up-front and earn-out payments. Biopharma fundraising dipped in December, while device financing increased for the second month in a row.

BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (2/2012)

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Medical Device BioPharmaceutical

Teva Backs Off From Big Acquisitions In 2012, But Isn't Done Spending Just Yet

Teva brought in Cephalon and a vastly expanded Japanese operation in 2011, and now the company expects to carve out local deals in new markets, execs tell investors during the annual JP Morgan Healthcare Conference.

BioPharmaceutical Deals

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011

Of the $6.3 billion total raised, 32% was from China distributor Shanghai Pharmaceuticals' $1.99 billion IPO - not only Q2's biggest financing, but also the second-largest pharma IPO of all time. Six of the 26 completed mergers were done to gain access to emerging markets, most notably, Takeda's $13.7 billion buy of Nycomed, almost half of the total $27.9 billion spent on pharma acquisitions this quarter. Q2's largest alliance was Vertex's in-licensing of Alios BioPharma's preclinical HCV nucleotide analogues, a deal that could be worth up to $775 million in up fronts and development milestones.
BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Mepha AG
  • Mepha Pharma AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Teva Pharmaceutical Industries Ltd.
  • Senior Management
  • Andreas Bosshard, Gen. Mgr.
  • Contact Info
  • Mepha LLC
    Phone: (41) 61 701 4343
    Dornacherstrasse 114
    P.O. Box 445 Aesch, CH-4147
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register